Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.
Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.
**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**
Priority Technology Holdings posted Q4 adjusted EPS of $0.27, up 621% year-over-year, with revenue climbing 8.8% to $247.1 million.
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential improvement.
Septerna reports Q4 loss of $0.24/share, wider than expected, as revenue climbs to $24.1M from minimal levels earlier in fiscal…
BETA Technologies reported a Q4 loss of $1.71/share vs expected $0.47 loss, but guided 2026 revenue to $130M-$135M as certification…
FuelCell Energy narrows Q1 loss to $0.52/share vs $0.68 estimate, but revenue of $30.5M misses $43.3M consensus by 29.5% on…
Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing zero growth.
Yalla Group's Q4 adjusted EPS of $0.21 and revenue of $83.9M matched the prior quarter exactly, signaling a growth plateau.